Exclusive Summary

• Listed on the WHO Model List of Essential Medicines (EML), phenytoin is a classic anti-epileptic staple representing massive, rigid global procurement demand.
• With over 50 million epilepsy patients globally (80% in low- and middle-income countries), it offers tremendous potential for emerging market distribution and government tenders due to significant treatment gaps.
• As all originator patents have expired, distributors can leverage China's scalable supply chain to fill prevailing market shortages caused by multinational pharma companies scaling down production.
• The 0.1g * 100 tablets/bottle specification perfectly aligns with long-term prescription tracking for chronic care, maximizing dispensing efficiency for large hospital networks and institutional buyers.